---
document_datetime: 2025-07-21 17:53:48
document_pages: 1
document_pathfilename: www.ema.europa.eu/en/documents/all-authorised-presentations/yesafili-epar-all-authorised-presentations_en.pdf
document_name: yesafili-epar-all-authorised-presentations_en.pdf
version: success
processing_time: 0.8393347
conversion_datetime: 2025-12-22 09:16:08.571376
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.64.1
  docling-core: 2.55.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
| MA (EU) number   | (Invented) name   | Strength   | Pharmaceutical Form    | Route of Administration   | Immediate Packaging        | Content (concentration)   | Pack size                                                |
|------------------|-------------------|------------|------------------------|---------------------------|----------------------------|---------------------------|----------------------------------------------------------|
| EU/1/23/1751/001 | Yesafili          | 40 mg/ml   | Solution for injection | Intravitreal use          | vial (glass)               | 0.1 mL                    | 1 vial + 1 filter needle                                 |
| EU/1/23/1751/002 | Yesafili          | 40 mg/ml   | Solution for injection | Intravitreal use          | vial (glass)               | 0.1 mL                    | 1 vial + 1 filter needle +1 syringe + 1 injection needle |
| EU/1/23/1751/003 | Yesafili          | 40 mg/ml   | Solution for injection | Intravitreal use          | Pre-filled syringe (glass) | 0.1 mL                    | 1 pre-filled syringe                                     |

1